AKTX Akari Therapeutics Plc

-0.1  -4%
Previous Close 2.63
Open 2.63
Price To Book 12.65
Market Cap 40118210
Shares 15,857,000
Volume 165,108
Short Ratio
Av. Daily Volume 3,098,346

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due 2019.
Coversin - CAPSTONE
Paroxysmal nocturnal hemoglobinuria (PNH)
Phase 1/2 interim update noted April 26, 2019. No serious drug related adverse events and good tolerability.
Atopic keratoconjunctivitis
Phase 2 data initial positive data released April 23, 2019.
Bullous Pemphigoid
Noted April 23, 2019 that trial has been placed on hold to focus on TMA space. Pivotal HSCT-TMA trial to be initiated 4Q 2019.
Atypical hemolytic-uremic syndrome (aHUS)

Latest News

  1. FDA Events Put Healthcare Stocks In The Headlines: Here's One That No One's Talking About Yet
  2. Akari Therapeutics Announces Expanded Ophthalmology Program Based on Positive Emerging Data on LTB4-C5 Dual Action in Surface and Back of the Eye Diseases
  3. The Daily Biotech Pulse: FDA Greenlights AbbVie's Psoriasis Drug, Novartis Earnings, Patent Notification For MediciNova
  4. Akari Reports Fourth Quarter and Full Year 2018 Financial Results and Business Highlights
  5. Positive News in The Biotech, Social Media, Financial & Cannabis Sectors Help the Market Towards New Highs
  6. Microcap Biotech Akari Rallies On Coversin Trial Results
  7. Akari Therapeutics Announces Positive Initial Phase II Clinical Data in Orphan Skin Disease Bullous Pemphigoid
  8. Akari Therapeutics to Provide Update on its Eye Disease Program During Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
  9. These Tech Stocks Could Test March Highs
  10. What Kind Of Shareholders Own Akari Therapeutics, Plc (NASDAQ:AKTX)?
  11. The Daily Biotech Pulse: Arsanis Completes X4 Merger, EC Nod For Roche, Axovant Offering
  12. These 4 Tech Stocks Are On The Rise On Wednesday (3/13/19)
  13. Akari Therapeutics' stock rockets on massive volume after 'successful' pre-IND FDA meeting
  14. Positive FDA Meeting Outlines Path Ahead for Akari Therapeutics’s Coversin in Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA)
  15. Factors of Influence in 2019, Key Indicators and Opportunity within EnLink Midstream, Pepsico, Arista Networks, Maiden, GCI Liberty, and Akari Therapeutics — New Research Emphasizes Economic Growth
  16. Alexion's (ALXN) Earnings Beat Estimates in Q4, Shares Up
  17. Alexion's Ultomiris Meets Primary Endpoint in aHUS Study
  18. What You Must Know About Akari Therapeutics, Plc’s (NASDAQ:AKTX) Beta Value
  19. Akari Therapeutics Announces New Data Highlighting Differentiation of Drug Candidate Coversin
  20. Akari Announces Coversin Data to be Presented at 2018 Complement-Based Drug Development Summit